Literature DB >> 16985938

Hormone treatments and preventive strategies in the aging male: whom and when to treat?

Jeremy Pw Heaton.   

Abstract

Sex hormones have a broad range of actions in regulating very diverse systems throughout life. Testosterone and other related hormones change with age to varying degrees and may induce pathophysiological changes and the clinical condition known as andropause. Androgen replacement is the accepted but not the only possible treatment for andropause. The presence of clinical symptoms, including a loss of sexual function, intellectual capacity, lean body mass, or bone mineral density; alterations in body hair, skin, or sleep pattern; or increases in visceral fat, together with low levels of serum testosterone characterize andropause. An appreciation of the potentially undesirable impact of androgens on the biology of prostate cancer, as well as possibly the cardiovascular system, is necessary. However, proper evaluation of aging men with symptoms of andropause will result in a decision to initiate androgen therapy in some aging men.

Entities:  

Year:  2003        PMID: 16985938      PMCID: PMC1502318     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  16 in total

1.  A critical evaluation of simple methods for the estimation of free testosterone in serum.

Authors:  A Vermeulen; L Verdonck; J M Kaufman
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

Review 2.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty.

Authors:  W B Ershler; E T Keller
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

Review 3.  Andropause: coming of age for an old concept?

Authors:  J P Heaton
Journal:  Curr Opin Urol       Date:  2001-11       Impact factor: 2.309

4.  Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male.

Authors:  A Morales; B Lunenfeld
Journal:  Aging Male       Date:  2002-06       Impact factor: 5.892

5.  Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities.

Authors:  G M Alexander; R S Swerdloff; C Wang; T Davidson; V McDonald; B Steiner; M Hines
Journal:  Horm Behav       Date:  1998-04       Impact factor: 3.587

6.  Hormonal erectile dysfunction. Evaluation and management.

Authors:  A Morales; J P Heaton
Journal:  Urol Clin North Am       Date:  2001-05       Impact factor: 2.241

7.  Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.

Authors:  J S Finkelstein; A Klibanski; R M Neer; S H Doppelt; D I Rosenthal; G V Segre; W F Crowley
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

8.  Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones.

Authors:  M Garaulet; F Pérex-Llamas; T Fuente; S Zamora; F J Tebar
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

9.  Validation of a screening questionnaire for androgen deficiency in aging males.

Authors:  J E Morley; E Charlton; P Patrick; F E Kaiser; P Cadeau; D McCready; H M Perry
Journal:  Metabolism       Date:  2000-09       Impact factor: 8.694

10.  Circadian abnormalities in older adults.

Authors:  S D Youngstedt; D F Kripke; J A Elliott; M R Klauber
Journal:  J Pineal Res       Date:  2001-10       Impact factor: 13.007

View more
  8 in total

1.  Diagnosis of hypogonadism: clinical assessments and laboratory tests.

Authors:  Christina Carnegie
Journal:  Rev Urol       Date:  2004

2.  Aging and estradiol effects on gene expression in the medial preoptic area, bed nucleus of the stria terminalis, and posterodorsal medial amygdala of male rats.

Authors:  Victoria L Nutsch; Margaret R Bell; Ryan G Will; Weiling Yin; Andrew Wolfe; Ross Gillette; Juan M Dominguez; Andrea C Gore
Journal:  Mol Cell Endocrinol       Date:  2016-12-20       Impact factor: 4.102

3.  Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.

Authors:  Mack Roach; Kyounghwa Bae; Colleen Lawton; B J Donnelly; David Grignon; Gerald E Hanks; Arthur Porter; Herbert Lepor; Varagur Venketesan; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

4.  Chronic administration of androgens with actions at estrogen receptor beta have anti-anxiety and cognitive-enhancing effects in male rats.

Authors:  Danielle M Osborne; Kassandra Edinger; Cheryl A Frye
Journal:  Age (Dordr)       Date:  2009-03-05

5.  Chronic administration of androgens with actions at estrogen receptor beta have anti-anxiety and cognitive-enhancing effects in male rats.

Authors:  Danielle M Osborne; Kassandra Edinger; Cheryl A Frye
Journal:  Age (Dordr)       Date:  2009-08-15

6.  Evidence for the participation of calcium in non-genomic relaxations induced by androgenic steroids in rat vas deferens.

Authors:  S S L Lafayette; I Vladimirova; L Garcez-do-Carmo; P T Monteforte; A Caricati Neto; A Jurkiewicz
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

7.  Age-Related Changes in Zinc, Copper and Selenium Levels in the Human Prostate.

Authors:  Adam Daragó; Michał Klimczak; Joanna Stragierowicz; Mateusz Jobczyk; Anna Kilanowicz
Journal:  Nutrients       Date:  2021-04-21       Impact factor: 5.717

8.  Effect of amlodipine, a calcium channel antagonist, on gonadal steroid of male Wistar albino rats.

Authors:  F C Onwuka; Kc Patrick-I Wuanyanwu; C K Nnodu; O Erhabor
Journal:  J Exp Pharmacol       Date:  2010-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.